U.S. Markets open in 13 mins.

Novartis AG (NVS)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
85.03+0.26 (+0.31%)
At close: 4:02PM EDT

84.72 -0.32 (-0.37%)
Pre-Market: 9:13AM EDT

People also watch
GSKSNYAZNLLYABT
Full screen
Previous Close84.77
Open84.88
Bid84.98 x 400
Ask85.03 x 500
Day's Range84.80 - 85.27
52 Week Range66.93 - 86.90
Volume7,018
Avg. Volume2,265,685
Market Cap191.82B
Beta0.72
PE Ratio (TTM)31.97
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.72 (3.27%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research20 hours ago

    FDA Panel Votes To Approve CTL019, Positive Implications for CYRX

    Last week an FDA advisory panel voted unanimously (10-0) to approve CTL019 (tisagenlecleucel-T), a novel CAR-T cell immunotherapy developed by Novartis (NVS), for the treatment of children and young adults (ages 3 - 25) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).  B-cell ALL is a form of Leukemia (i.e.

  • Barrons.comyesterday

    [$$] Novartis, Glaxo and Lilly Bigly Back New Biotech

    Aileron Therapeutics’ initial public offering was priced at $15 a share on June 28. You can be forgiven if you hadn’t heard of the cancer biotech’s IPO. Apart from a low media profile, the low-end IPO pricing was also a disappointment.

  • Reutersyesterday

    Poor test results for Roche cloud growth prospects

    A run of disappointing drug trials at Roche has left analysts suggesting the view from its new 41-storey office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings. "Their impact in the second half might limit Roche's chances of upgrading 2017 guidance," he said.